Background: Human peripheral blood monocytes (Mo) consist of subsets distinguished by expression of CD16 (FCγRIII) and chemokine receptors. Classical CD16 -Mo express CCR2 and migrate in response to CCL2, while a minor CD16 + Mo subset expresses CD16 and CX3CR1 and migrates into tissues expressing CX3CL1. CD16 + Mo produce pro-inflammatory cytokines and are expanded in certain inflammatory conditions including sepsis and HIV infection.
Background
Peripheral blood monocytes (Mo) originate from hematopoietic progenitor cells in bone marrow and play important roles in innate and adaptive immunity due to their ability to differentiate into macrophages (MΦ) and dendritic cells (DC) [1] [2] [3] [4] [5] [6] [7] . The heterogeneity and plasticity of MΦ and DC result from their differentiation in specific tissue microenvironments [8] [9] [10] . The expression of CD16 (FcγRIII) distinguishes two Mo subsets in peripheral blood of healthy individuals: a major CD16subset (80-95%) and a minor CD16 + subset (5-15%) [11] . Compared to classical CD16 -Mo, CD16 + Mo exhibit a more MΦ-like morphology, produce higher levels of TNF and IL-1 [12, 13] , have higher antigen presenting potential [14] [15] [16] , and differentiate into DC upon transendothelial migration in vitro [17] . CD16 + Mo express CX3CR1 and migrate in response to CX3CL1 [18, 19] , a membranebound chemokine expressed on inflamed endothelial cells, while CD16 -Mo express CD62L and CCR2 and migrate in response to CCL2 [18, 20] , which mediates Mo migration from bone marrow and recruitment to inflammatory sites [2, 21] . CD16 + Mo produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells [22] and activate resting T-cells for HIV infection by producing CCR3 and CCR4 ligands [23] . Together, these findings suggest that CD16 + and CD16 -Mo are recruited into different anatomic sites under constitutive or inflammatory conditions, and play distinct functional roles in immunity and disease pathogenesis.
A dramatic increase in circulating CD16 -Mo has been reported in inflammatory pathologies such as sepsis, HIV infection, tuberculosis, and asthma [11, 24, 25] . Studies of patients infected with Mycobacterium leprae demonstrated that CD16 + and CD16 -Mo differentiate into DC-SIGN + MΦ and CD1b + DC-SIGN -DC, respectively, and the presence of CD1b + DC-SIGN -DC in M. leprae lesions was associated with healing [26] . An increased frequency of CD16 + Mo was associated with non-healing Leishmania chagasi lesions [27] . Thus, CD16 + and CD16 -Mo differentiation into MΦ or DC subpopulations with distinct phenotypes influences host defenses in infectious disease. Consequently, there is interest in developing therapeutic strategies that target specific Mo subpopulations [6, 8, 28, 29] .
Mo heterogeneity is conserved across mammalian species [7, 8, 19, 30] . In mice, Gr1 + CX3CR1 low Mo (homolog of human CD16 -Mo) are recruited into the peritoneal cavity or draining lymph nodes under inflammatory conditions by mechanisms dependent on CCR2 and CD62L, and subsequently differentiate into DC [19, [31] [32] [33] . In contrast, Gr1 -CX3CR1 high (homolog of human CD16 + Mo) are constitutively recruited into peripheral tissues including spleen, gut, lungs, and brain [19] . Gr1 -CX3CR1 high patrol vascular endothelium by mechanisms involving LFA-1 and CX3CR1, and are rapidly recruited into inflamed tissues where they differentiate into MΦ expressing the transcription factors cMaf and MafB and transiently producing TNF-α [33] . Studies in CX3CR1/ApoE double knockout mice suggest that CX3CR1 high Mo play a critical role in development of atherosclerotic lesions [34, 35] . CX3CR1 + Mo may be precursors for lamina propria DC, which depend on CX3CR1 to form transepithelial dendrites, enabling direct sampling of luminal antigens [36] . Furthermore, adoptive transfer studies in rats demonstrated that CCR2 low CX3CR1 high Mo are constitutively recruited into the gut where they give rise to intestinal lymph DC [37] . Studies on the origin of myeloid pulmonary DC demonstrated that Ly-6C high CCR2 high CX3CR1 low Mo differentiate into CD103 + DC [38, 39] ), whereas Ly-6C low CCR2 low CX3CR1 high Mo give rise to CD11b high DC [39, 40] . Thus, CX3CR1 high and CX3CR1 low Mo subsets play distinct functional roles under constitutive and inflammatory conditions. The developmental relationship between Mo subsets is poorly understood. In mice, Mo recently emigrating from bone marrow exhibit a Ly-6C high phenotype and gradually downregulate Ly-6C [41] . Mo acquire CD16 expression upon exposure to M-CSF [42] , TGF-β [17, 43] , or IL-10 [44] , and upregulate CX3CR1 expression upon CCL2 stimulation via CCR2 [45] . Mo differentiation is associated with decreased CCR2 expression and increased CCL2 production [46] . Engrafted Gr1 high CX3CR1 low Mo in peripheral blood traffic to the bone marrow, differentiate into Gr1 low CX3CR1 high Mo, and contribute to mucosal, but not splenic, generation of DC [5] . These findings suggest that human CD16 + Mo and mouse Ly-6C low CCR2 low CX3CR1 high Mo differentiate from CD16 -Mo and Gr1 -Ly-6C high CCR2 high CX3CR1 low Mo, respectively.
Here, we investigate the developmental and functional relationship between CD16 + and CD16 -Mo subsets. Whole genome transcriptome analysis suggests that these Mo subsets originate from a common myeloid precursor, with CD16 + Mo being at a more advanced stage of differentiation and having a more MΦ -and DC-like transcription program. Upregulation of the transcription factors RARA and KLF2 in CD16 + Mo coincided with the absence of cutaneous lymphocyte associated antigen (CLA) expression, indicating potential imprinting for non-skin homing in CD16 + Mo. These results define distinct transcriptional profiles of CD16and CD16 + Mo subsets suggesting different stages of myeloid differentiation, new markers to distinguish these Mo subpopulations, and unique roles in immune responses and inflammatory diseases.
Methods

Antibodies
Fluorochrome-conjugated Abs used for FACS analysis were CD14, CD16, CD19, CD16b, CD66b, CD56, and CD3 (Beckman Coulter); M-DC8 and CD1c (Miltenyi), HLA-DR, CD114, C3aR, CD1d and CD43 (BD Pharmingen), CD115 (R&D Systems), CD93/C1qR1 (Chemicon International), and CXCL16 (R&D Systems). Matched isotype controls were from the same source as the Abs.
Flow cytometry analysis
Blood from healthy individuals was collected with informed consent and IRB approval from Dana-Farber Cancer Institute. PBMC isolated from peripheral blood by Ficoll-Paque gradient density centrifugation were stained with fluorochrome-conjugated Abs and analyzed by multi-color flow cytometry (BD FACSCalibur or LSRII).
Monocyte sorting
Monocytes (Mo) were isolated by negative selection using magnetic immunobeads (Monocyte Isolation Kit II, Miltenyi) as described [18, 47] . The purity of sorted Mo was >98%, as determined by FACS analysis indicating the expression of CD14 and HLA-DR (monocyte markers) and absence of CD1c (DC marker), CD56 (NK cell marker), CD19 (B cell marker), CD3 (T cell marker), and CD16b and CD66b (neutrophil markers) expression. CD16 + and CD16 -Mo fractions were further isolated using CD16 magnetic immunobeads (Miltenyi) with >85% and >95% purity for CD16 + and CD16 -Mo fractions, respectively, as determined by FACS analysis after staining with CD16 Abs [23] . Mo fractions isolated under RNase free conditions were stored in Trizol at -80°C for subsequent RNA extraction.
RNA isolation and microarray analysis
Total RNA from Mo pellets was isolated by Trizol extraction and purified using RNeasy columns (Qiagen). The quality of RNA was assessed by visualization of intact bands corresponding to 18S and 28S rRNA on formaldehyde agarose gels. Total RNA (10 μg) from matched CD16 + and CD16 -Mo samples isolated from 4 different healthy donors was quality tested using an Agilent 2100 Bioanalyzer chip, reverse transcribed, and hybridized on the GeneChip ® Human Genome U133 Plus 2.0 Array (Affymetrix), which includes 54,000 probe sets on a single array (i.e., 47,000 transcripts and variants, including 38,500 well-characterized human genes). Primary data analysis performed using GeneSpring software (Biopolymer core facility, Harvard Medical School) generated Excel spreadsheets with relative gene expression values for the 4 matched CD16 + and CD16 -Mo subsets.
Microarray data analysis
A total of 16,328 probe sets were detected in these 8 samples (present calls, defined as probe sets detected in at least 3 samples). Normalization was performed as described [48] to account for variation between microarrays. Missing value estimation was performed using a modified KNN algorithm [49, 50] . T-test was used to identify probe sets differentially expressed in CD16 + and CD16 -Mo (p < 0.05). These genes were sorted according to their t-statistics and fold change ratios, which were calculated by computing the mean expression in CD16 + and CD16 -Mo. Clustering analysis using fuzzy-c-means [50, 51] was performed based on the genes selected by Ftest (n = 2,759 probe sets). False discovery rates (FDR) [52] were estimated using dChip software (build date: Jan 27 2009) [53] by performing 100 random permutations using all 8 samples with p-values < 0.05, expression ratio cut-off = 2.0-fold, and present call cut-off of 20%, yielding a median FDR of 0.07. Expression ratios for differentially expressed probe sets were calculated in CD16 + versus CD16 -Mo (cut-off 2-fold; p < 0.05). Heat maps for biological function categories were generated by dChip software using signal values from each of the 8 samples for genes that were > 2-fold upregulated or downregulated in CD16 + Mo compared to CD16 -Mo. The entire microarray dataset and technical information requested by Minimum Information about a Microarray Experiment (MIAME) are available at the Gene Expression Omnibus (GEO) database under accession number GSE16836 (Transcriptional profiling of CD16 + and CD16peripheral blood monocytes from healthy individuals) http://www.ncbi.nlm.nih.gov/geo.
Gene set enrichment analysis (GSEA)
Gene set enrichment analysis (GSEA) and Molecular Signature DataBase (MSigDB) http://www.broad.mit.edu were used to identify differentially expressed gene sets [54] . GSEA is a computational method that determines whether an a priori defined set of genes shows statistically significant concordant differences between two biological states (e.g. phenotypes). MSigDB contains more than 3000 gene sets for use with GSEA. An enrichment score (ES) that represents the difference between the observed and expected rankings from phenotype correlation was calculated for every gene set. A nominal p-value for the specific ES was then estimated from an empirical permutation-based null distribution that preserves the complex correlation structure of the gene expression data. Multiple testing was corrected via the FDR, with FDR less than 10% considered statistically significant.
Quantitative Real time RT-PCR
One step SYBR Green real time RT-PCR (Qiagen) was carried out in an iCycler BioRad EN270 PCR machine according to manufacturer's recommendations. Absolute quantification of target gene expression was performed using a 10-fold serial dilution of purified PCR products as described [55] . Briefly, 25-50 ng total RNA was reverse transcribed in 25 μl 1× SYBR Green mix (Qiagen) containing 0.5 μM primers, and 10 nM fluorescein calibration dye (Bio-Rad). Agarose gel electrophoresis was used to determine the size of amplification products (100-200 bp) and allowed cDNA purification (QIAquick Gel Extraction Kit; Qiagen) for standard curve preparation (i.e., 200, 20, 2, 0.2, and 0.02 fg cDNA). Primers spanning one or multiple exons were purchased from Qiagen (i.e., SIGLEC10, MafB, C1QR, C3AR1, CDKN1C, CSF1R, CSF3R, FcγRIII, TNFRSF8, ICAM-2 QuantiTect primer sets). Samples without template and reverse transcriptase were used as negative controls. The concentration of each gene was normalized to the 28S ribosomal RNA (RRN28S) internal control [55] . Each RT-PCR reaction was performed in triplicate.
Results
Distinct gene expression profiles in CD16 + and CD16monocytes
To define transcriptional profiles of monocyte subsets in vivo, we performed genome wide transcriptome analysis of matched CD16 + and CD16 -Mo subsets in peripheral blood of four healthy individuals. We identified 2,759 probe sets that were differentially expressed and 13,569 genes that were similarly expressed in these Mo subsets ( Figure 1A ) (GEO database accession number GSE16836, http://www.ncbi.nlm.nih.gov/geo). Clustering analysis separated the 8 samples into 2 groups that perfectly matched CD16 + and CD16 -Mo, with 1,402 genes downregulated and 1,357 genes upregulated in CD16 + compared to CD16 -Mo ( Figure 1B ). Calculation of expression ratios for 2,759 differentially expressed probe sets showed that 250 probe sets were downregulated (corresponding to 166 genes and 23 unknown transcribed sequences) and 228 probe sets were upregulated (corresponding to 153 genes and 19 unknown transcribed sequences) in CD16 + compared to CD16 -Mo (cut-off 2-fold; p < 0.05) ( Figure  1C -D, Additional files 1, 2). These 2-fold lists of differentially expressed genes included known markers for CD16 + (i.e., FCGR3A/CD16, CX3CR1, ITGAL/LFA-1, and CD31/ PECAM1) and CD16 -Mo (i.e., CD14, CCR2, SELL/ CD62L, FCGR1/CD64) [18] [19] [20] (Additional files 1, 2), providing initial validation of microarray results. Signature transcripts for other blood cell lineages were absent in both CD16 + and CD16 -Mo (i.e., CD3 and CD8 for T cells, CD56 for NK cells, CD19 for B cells, and DC-SIGN and CD1c for DC), consistent with results obtained by flow cytometry demonstrating the purity of sorted Mo (>98%) and absence of DC (i.e., CD1c), NK cell (i.e., CD56), B cell (i.e., CD19), T cell (i.e., CD3), neutrophil (i.e., CD16b and CD66b) markers on CD16 + and CD16 -Mo. The difference in relative expression of some probe sets for donor #1 probably reflects normal donor-to-donor variability, since post-sort cell viability, RNA quality, and MicroArray Quality Controls were similar for the four donors. A more stringent analysis was performed where in addition to a cut-off >2-fold and p-value < 0.05, probe sets with expression levels >3-fold higher than background were selected; by this approach, we identified 132 downregulated and 183 upregulated probe sets in CD16 + compared to CD16 -Mo (data not shown). These genes were further selected for those with the highest levels of expression (>10,000 AU (arbitrary units), cut-off >2-fold; p-value < 0.05) and two lists of top genes were generated, with 30 and 31 transcripts upregulated in CD16 + and CD16 -Mo, respectively (Tables 1 and 2). Other genes were differentially expressed with a difference <2-fold. In CD16 + compared to CD16 -Mo, downregulated markers included the early myeloid markers CD13 (2,971 ± 1,753 versus 5,656 ± 2,392; ratio 0.53, p-value < 0.05) and CD33 (1,860 ± 703 versus 3,478 ± 686; ratio 0.52, p-value < 0.05). Thus, despite a high level of transcriptional similarity (approximately 83%), a subset of probe sets were significantly downregulated (n = 250) or upregulated (n = 228) in CD16 + compared to CD16 -Mo, suggesting that these Mo subsets represent different stages of myeloid differentiation and have distinct biological functions in vivo.
Validation of microarray results and identification of new surface markers that distinguish CD16 + and CD16monocytes
Real time RT-PCR was used to quantify expression of nine differentially expressed genes identified by microarray analysis. Results in Figure 2 indicate increased mRNA expression for CD16, C3AR1, ICAM-2, CSF1R, CDKN1C, TNFRSF8, and LTB, and decreased mRNA expression for C1QR1 and CSF3R in CD16 + compared to CD16 -Mo (unpaired t-test, p < 0.05, CD16 + versus CD16 -Mo). Microarray results were also validated at the protein level by flow cytometry analysis. Consistent with the microarray and real time RT-PCR results (Figures 1, 2) , FACS analysis demonstrated that CD14 low CD16 + (gate R3) compared to classical CD14 high CD16 -Mo (gate R2) expressed higher levels of CD115/CSFR1 (M-CSF receptor) and C3AR1, and lower levels of CD114/CSF3R (G-CSF receptor) and CD93/C1qR1 on the cell surface ( Figure 3A (Additional file 3 ). In addition, CD16 + compared to CD16 -Mo expressed higher levels of CXCL16 and CD43 and lower levels of CD1d ( Figure 4A -C). As expected, CX3CR1 was also expressed at higher levels ( Figure 4D ). Thus, we identified new surface markers that distinguish CD16 -Mo (i.e., CD114, CD93, and CD1d) and CD16 + Mo (i.e., CD115, C3AR1, CXCL16, and CD43).
Biological functions of differentially expressed genes
Differentially expressed genes, corresponding to 250 downregulated and 228 upregulated probe sets in CD16 + compared to CD16 -Mo, were classified into eight functional categories using Gene Ontology. Heat maps for biological function categories ( Figure 5A -H) showed clear distinctions in patterns of gene expression between the Mo subpopulations for these categories.
Adhesion molecules, chemokines, and chemokine receptors
Genes upregulated in CD16 + compared to CD16 -Mo included those coding for the tetraspanins MS4A4A and MS4A7, adhesion molecules SIGLEC10, ICAM-2, SPN/ CD43, ITGAL/LFA-1/CD11a, CD47, and PCAM1/CD31, chemokine receptor CX3CR1, and chemokine CXCL16 [56] . Genes downregulated in CD16 + compared to CD16 -Mo included those coding for the tetraspanin MS4A6A, adhesion molecules ITGAM/CD11b, SELL/L-selectin/ CD62L, CD99, and junctional adhesion molecule like (JAML or AMICA) [57] , and chemokine receptors CCR1, CCR2, and formyl peptide receptor 1 (FPR1) ( Figure 5A ). These results identify SIGLEC10, ICAM-2, SPN/CD43, CD47, and CXCL16 as new markers upregulated on CD16 + Mo that are relevant for T cell activation, and FPR1 as a chemokine receptor preferentially expressed on CD16 -Mo. In addition, these results indicate the distinct trafficking potential of CD16 + and CD16 -Mo (i.e., via CX3CR1 versus CCR2, respectively), consistent with previous studies [18] [19] [20] .
Cytokines and cytokine receptors CD16 + Mo expressed significantly higher levels of mRNA for the cytokines lymphotoxin beta (LTB) and leukocyte specific transcript 1 (LST1) and the cytokine receptors TNF receptor superfamily 8 (TNFRSF8), prostaglandin E receptor 4 (PTGER4), colony stimulating factor 1 receptor (CSF1R; CSF1, controls Mo/MΦ differentiation and function), and IL-12RB1. Genes downregulated in CD16 + Mo included those coding for the cytokine IL-1RA, plateletactivating factor receptor (PTAFR), and IL1B and cytokine receptors IL13RA1, IL27RA (WSX1), colony stimulating factor 3 receptor (CSF3R; CSF3 controls granulocytes differentiation and function), IL6R, and IL6ST/gp130 (a signal transducer shared by many cytokines, including IL-6 and IL-27) ( Figure 5B ). These results provide further evidence for pro-inflammatory genes upregulated in CD16 + Mo (e.g., HMOX1 and SOD1) [12] and suggest the ability of CD16 + and CD16 -Mo to respond to distinct cytokines including IL-12 [58] and IL-13 [59] and IL-6 and IL-27 [60, 61] , respectively, which has potential implications for Th1 and Th2 polarization of immune responses. In addition, these results identify CSF1R and CSF3R as new markers for CD16 + and CD16 -Mo, respectively, with potential implications for their differentiation fate in vivo.
Immune responses, inflammation, and complement CD16 + Mo expressed significantly higher levels of mRNA for the low affinity Fcγ receptor FCGR3A/CD16, IFN-γinduced surface molecules IFITM1, IFITM2 and IFITM3, complement receptor C3AR1, arrestin beta 1 (ARRB1, which contributes to desensitization of G-protein-coupled receptors), and CD97 (receptor for complement decay accelerating factor, DAF/CD55). Genes downregulated in CD16 + Mo included those coding for the high affinity Fcγ receptor FCGR1A/CD64, complement receptor C1QR1, Ca binding proteins S100A12, S100A9, and S100A8, phospholipase A2, group VII (PLA2G7), Ig superfamily receptor TREM1, neutrophil cytosolic factors NCF1 and NCF4, heparanase (HPSE), chondroitin sulfate proteoglycan 2 (versican, CSPG2), amyloid beta (A4) precursor-like protein 2 (APLP2) involved in turnover of MHC Class I molecules [62] , amyloid beta (A4) precursor protein (APP), and aquaporin AQP9, which plays a role in immunological response and bactericidal activity ( Figure  5C ). These results identify complement-related molecules C3AR1 and CD97 as new markers for CD16 + Mo, and C1QR1 as a new marker for CD16 -Mo.
Metabolism and stress response
Transcripts upregulated in CD16 + Mo included genes related to protein synthesis (i.e., tryptophanyl-tRNA synthetase (WARS)), protein catabolism (i.e., cathepsin L (CTSL), cathepsin C (CTSC)), stress responses (i.e., heme Differential expression of CD1d, CD43, CXCL16, and CX3CR1 on CD16 + and CD16monocytes Figure 4 Differential expression of CD1d, CD43, CXCL16, and CX3CR1 on CD16 + and CD16monocytes. Freshly isolated PBMC were stained with Pacific Blue CD3, Alexa700 CD4, FITC CD14, PE-Cy5 CD16, and PE CD1d, PE CD43, PE CXCL16 or PE CX3CR1 Abs. Gated CD3 -CD4 low CD14 high CD16 -(CD16 -Mo) and CD3 -CD4 low CD14 low CD16 + (CD16 + Mo) cells were analyzed for expression of (A) CD1d, (B) CD43, (C) CXCL16, and (D) CX3CR1. Shown are representative dot plots (left panels) and results for 9-13 different donors (right panels). Paired Wilcoxon signed rank test was used to calculated statistical significance (p < 0.05, CD16 + versus CD16 -Mo). (sulfamidase)/SGSH), stress responses (i.e., aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), glutathione peroxidase 1 (GPX1), tumor necrosis factor, alpha-induced protein 3 (TNFAIP3), and aldehyde dehydrogenase 2 family (ALDH2)) and other enzymatic processes (i.e., ribonuclease, RNase A family, 2 (RNASE2) and lysozyme (LYZ)) ( Figure 5D ). Differential Biological functions of genes differentially expressed in CD16 + and CD16monocytes Figure 5 Biological functions of genes differentially expressed in CD16 + and CD16monocytes. Differentially expressed genes were classified based on their biological functions using Gene Ontology as indicated. Heat maps were generated using dChip software and include data from matched CD16 + and CD16 -Mo from 4 different individuals. In each heat map, upregulated genes are plotted first followed by downregulated genes. Red and green signify increased and decreased gene expression, respectively .   CUTL1  INSIG1  SFMBT2  CTSL  HMOX1  DUSP5  SES1  PAG  PAPSS2  LIMD1  NAP1L1  PLAGL2  PIK3CG  SNX9  KIAA1959  MERTK  GUCY1B3  DKFZP727G051  SOD1  RUNX3  MGC16202  LOC122618  LYN  HSPH1  ULK2  ABHD6  KLF2  DUSP7  WARS  GCH1  MADH1  AP2A1  DRAP1  CTSC  MGLL  ULK2  SH3MD2  RYBP  PPGB  DPYD  ADM  SGSH  BCL3  TGIF  TALDO1  IDH1  P4HB  ALDH2  SORL1  PGD  LYZ  PPIF  TNFAIP3  NFE2  USP15  PSTPIP1  CIDEB  MGC26963  SGKL  RAB27A  BLVRB  PRKAR2B  MGC39820  SGK  HEXB  PHLDA2  CPD  HOMER3  GPX1  ID1  BST1  CAPG  SMA3  GM2A  ALDH1A1  CYP1B1  SLC2A14  RNASE2  MGST1  SLC2A3  QPCT   D. METABOLISM   STRESS RESPONSE   B.CYTOKINES   CYTOKINE RECEPTORS   CDKN1C  MTSS1  NAP1L1  TBC1D8  BCL3  MNDA  JAG1  CD1D  PLP2  BST1  EREG  IER3   F. CELL CYCLE   PROLIFERATION  DIFFERENTIATION   EVL  UTRN  RUNX3  CDC42EP4  MAP4  SVIL  ARHF  RAPH1  CKAP4  DSC2  LMNB1  CAPG  ACTN1   G.CYTOSKELETON   FCGR3A  IFITM1  IFITM2  IFITM3  C3AR1  ARRB1  CD97  AQP9  APP  APLP2  FCGR1A  S100A8  C1QR1  NCF4  S100A9  HPSE  NCF1  TREM1  CD36  PLA2G7  CSPG2  S100A12   C. IMMUNE RESPONSES   INFLAMMATION  COMPLEMENT   CUTL1  TCF7L2  SFMBT2  RUNX3  PHTF2  LIMD1  PLAGL2  MAFB  DKFZP727G051  PSCDBP  KLF2  RARA  MADH1  DRAP1  POU2F2  NFATC1  RYBP  TGIF  HIF1A  NFE2  SAP30  AHR  ID1  TFEC   H.TRANSCRIPTION   LTB  TNFRSF8  PTGER4  CSF1R  LST1  IL12RB1  WSX1  IL6R  PTAFR  IL1B  FPR1  IL1RN  IL6ST  CSF3R  IL13RA1   MS4A4A  SIGLEC10  MS4A7  ICAM2  SPN  CX3CR1  ITGAL  CXCL16  CD47  PECAM1  AMICA  CCR1  FPR1  SELL  ITGAM  MS4A6A  CD99  CCR2   A.ADHESION MOLECULES   CHEMOKINES  CHEMOKINE RECEPTORS   E. SIGNALING   SIGNAL TRANSDUCTION   MGC19531  PTP4A3  EVL  RUNX3  EMR2  EMR1  PAG  CTL2  RRAS  LIMD1  SH2D3C  PIK3CG  SNX9  RTN2  MERTK  P2RX1  RASGRP2  MADH1  ARHF  CENTD1  LYN  RAPH1  LIM  ADM  BCL3  TGIF  MAP2K6  FLJ20186  PSTPIP1  CIDEB  SGKL  PRKAR2B  HSPC195  JAG1  GRN  RAB27A  GPR160  NRGN  IL6ST expression of SOD1 and GPX1 in CD16 + and CD16 -Mo, respectively, indicates a distinct antioxidant enzymatic defense system in these Mo subsets. The upregulation of WARS expression in CD16 + Mo suggests increased potential protein synthesis [63] , while CTSL and CTSC upregulation may indicate increased potential antigenic processing and antigen presentation capacity [64] .
Signaling and signal transduction CD16 + Mo expressed significantly higher levels of transcripts for a large number of genes involved in signal transduction including the protein tyrosine phosphatase type IVA, member 3 (PTP4A3) and phosphoinositide-3kinase, catalytic, gamma polypeptide (PIK3CG, a crucial signaling molecule required for macrophage accumulation in inflammation [65] ). Genes downregulated in CD16 + Mo included those coding for the interleukin 6 signal transducer (IL6ST), G protein-coupled receptor 160 (GPR160), jagged 1 (JAG1, the ligand for the receptor notch 1), protein kinase, cAMP-dependent, regulatory, type II, beta (PRKAR2B), the CD2 binding protein proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1), and mitogen-activated protein kinase kinase 6 (MAP2K6) ( Figure 5E ). Thus, CD16 + and CD16 -Mo exhibit distinct signaling pathway activation, indicating a distinct activation/differentiation history in vivo.
Cell cycle, proliferation and differentiation CD16 + Mo were distinguished from CD16 -Mo by upregulation of the cell cycle related genes cyclin-dependent kinase inhibitor 1C (CDKN1C, p27, or KIP2, which is a negative regulator of cell proliferation [66] induced by TGF-β [67] ), and metastasis suppressor 1 (MTSS1, a transcript involved in cytoskeleton organization missing in metastasis [68] ). CD16 -Mo preferentially expressed mRNA for genes encoding the CD1d antigen (member of the MHC family that mediates presentation of primarily lipid/glycolipid antigens to T cells), and myeloid cell nuclear differentiation antigen (MNDA, which is expressed in human monocytes and granulocytes and earlier stage cells in the myeloid lineage [69] ) ( Figure 5F ). These results provide evidence that CD16 + Mo represent a more advanced stage of differentiation compared to CD16 -Mo.
Cytoskeleton CD16 + were distinguished from CD16 -Mo by expression of a series of genes related to the cytoskeleton showing higher expression in CD16 + Mo including CDC42 effector protein (Rho GTPase binding) 4 (CDC42EP4), microtubule-associated protein 4 (MAP4), and supervillin (SVIL) and in CD16 -Mo including actinin, alpha 1 (ACTN1). ( Figure 5G ).
Transcription factors CD16 + Mo expressed significantly higher levels of mRNA for several transcriptional factor genes including the macrophage transcription factor v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MafB, an essential determinant of the monocytic program in hematopoietic cells [7, 70, 71] ), the pleckstrin homology, Sec7, and coiled-coil protein-binding protein (PSCDBP or CYBR, a cytohesin-1-binding protein expressed in NK cells stimulated with IL-2 and IL-12 that plays a role in integrinmediated cell adhesion [72] ), the Kruppel-like factor 2 (KLF2, reported to license mature T-cells for trafficking from the thymus and recirculation through secondary lymphoid tissues [73] ), and retinoic acid receptor, alpha (RARA, expressed in dendritic cells [74] and involved in myeloid differentiation [75] and imprinting for gut homing [76, 77] ). In contrast, CD16 -Mo preferentially expressed the aryl hydrocarbon receptor (AHR, a ligand dependent E3 ubiquitin ligase [78] and modulator of anti-viral immunity [79] ) transcript ( Figure 5H ). Both CD16 + and CD16 -Mo lacked PU.1 expression, a transcription factor upregulated in DC [71] , as demonstrated by microarray analysis and RT-PCR (data not shown). Thus, CD16 + and CD16 -Mo express distinct transcription factors that may differentially regulate biological functions in vivo.
Gene set enrichment analysis (GSEA)
To extract further meaning from differentially expressed genes in CD16 + and CD16 -Mo, GSEA, a knowledge based approach for interpreting genome-wide expression profiles [54] , was applied to test for sets of genes that share common biological functions. Enrichment scores (ES), nominal p-values, false discovery rate (FDR), and family wise-error rate (FWER) values were generated for a large number of gene sets for GSEA available on the Molecular Signatures Database (MSigDB) of the Broad Institute. One gene set was significantly enriched in CD16compared to CD16 + Mo: HADDAD_HPCLYMPHO_ENRICHED (p < 0.001; both FDR q-value and FWER p-value-< 0.2). According to MSigDB, this set includes genes enriched in CD45RA hi Lin -CD10 + versus CD45RA int CD7and CD45RA hi CD7 hi hematopoietic progenitor cells [80] . Four uncharacterized open reading frames upregulated in hematopoietic progenitor cells (i.e., C18ORF1, CYORF15B, C6ORF62, and C6ORF111) [80] were significantly enriched in CD16 -Mo.
GSEA also identified several gene sets relatively enriched in CD16 + or CD16 -Mo, but with a lower statistical significance likely related to the limited number of samples (p < 0.001 and FDR = 1). These analyses showed that CD16 + Mo were enriched in genes related to NK cell mediated toxicity (i.e., FcγRIIIA, PIK3CG, NFATC1, ITGAL, and ICAM-2), inositol phosphate metabolism (i.e., PIK3CG), actin binding (i.e., MTSS1, COTL1, and SVIL), and oxidative stress (i.e., CDKN1C, ETS1, CD47, LYN, and VIL2). In contrast, CD16 -Mo were enriched in genes related to hematopoietic cell lineage (i.e., CD1d, IL1β, FcγRIA, ITGAM, CSF3R, CD36, and CD14), receptor mediated endocytosis (i.e., SORL1, STAB1, FCGR1A, and CD14), arginine and proline metabolism (i.e., ALDH2, P4HB, and ALDH1A1), nontypable Haemophilus influenzae (NTHi) pathway (i.e., IL1B and MAP2K6), and lipid binding molecules (i.e., CD1D, PTAFR, ALDH1A1, and PLA2G7). Overall, these results provide new insights into the developmental relationship between CD16 + and CD16 -Mo, with CD16 -Mo being more closely related to hematopoietic progenitor cells and having higher endocytosis activity, while CD16 + Mo being at a more advanced stage of Mo differentiation with more effector functions related to antigen presentation, migration, and cytotoxicity.
Pattern recognition receptor expression in CD16 + and CD16monocytes
Both Mo subsets expressed TLR1, TLR2, TLR4, TLR5, and TLR8 but not TLR3, TLR6, TLR7, TLR9, and TLR10 mRNA (data not shown). Considering that CD16 + Mo express low levels of the LPS co-receptor, CD14 [11] , and that TLR stimulation was previously implicated in myeloid differentiation [26, 81] , we tested whether genes associated with TLR pathway were upregulated in these cells. However, GSEA rejected this hypothesis. Nonetheless, microarray results demonstrated slight downregulation of TLR2, TLR4, TLR5, and TLR8, together with slight upregulation of MyD88, a key adaptor for these TLRs [82] , in CD16 + compared to CD16 -Mo
Potential imprinting for non-skin homing in CD16 + monocytes
We demonstrated increased expression of RARA mRNA in CD16 + compared to CD16 -Mo ( Figure 5H and 6A ). SLP-76 (Src-homology 2 domain-containing leukocyte specific phosphoprotein of 76 kDa), a RA-induced target [75] , was significantly upregulated in CD16 + compared to CD16 -Mo (6363 ± 611 versus 3882 ± 565; CD16 + /CD16ratio 1.64; p = 0.005), indicative of RARA pathway activation in CD16 + Mo. Activation of the RARA transcription factor pathway leads to loss of skin homing potential in lymphocytes via downregulation of the cutaneous lymphocyte-associated antigen (CLA, an epitope on PSGL-1) [83] and imprinting for mucosal homing [77] . CLA expression was quantified on CD16 + and CD16 -Mo by FACS on PBMC from healthy individuals. CLA expression was undetectable on all CD16 + Mo and a fraction of CD16 -Mo ( Figure 6B ). The frequency of CLA + CD16 -Mo was negatively correlated with the frequency of CD16 + Mo ( Figure 6C ). CD16 + Mo express M-DC8 (an epitope on PSGL-1) [13] , which was previously reported to be expressed by a subset of mucosal DC [84] ( Figure 6D ). CX3CR1 expression on CD16 + Mo ( Figure 4D ) [18] may contribute to recruitment of these cells into CX3CL1 expressing tissues including the gut. These results indicate that CD16 + Mo, similar to RA-stimulated T-cells [77] , lack expression of the skin-homing addressin CLA and therefore are potentially imprinted for non-skin homing. Because retinoic acid (RA) is an important factor driving myeloid differentiation [75] , this reprogramming of CD16 + Mo homing potential may be in part a consequence of RARA pathway activation.
Discussion
In this study, we define transcriptional profiles of human CD16 + and CD16monocytes (Mo) and provide new insights into their developmental relationship and biological functions. Despite remarkable transcriptional similarity (approximately 83%), a significant number of transcripts were differentially expressed (n = 2,759), with 228 and 250 >2-fold upregulated and downregulated, respectively, in CD16 + compared to CD16 -Mo. Differentially expressed genes related to cell-to-cell adhesion and trafficking, immune responses and inflammation, metabolism and stress response, signaling and signal transduction, cell cycle, proliferation, and differentiation, cytoskeleton, and regulation of transcription. Gene set enrichment analysis (GSEA) demonstrated that CD16 + Mo are enriched in genes related to NK-mediated cytotoxicity, inositol phosphate metabolism, actin binding, and oxidative stress, while CD16 -Mo are enriched in genes related to hematopoietic cell lineage, receptor-mediated endocytosis, arginine and proline metabolism, NTHi pathway, and lipid binding. The transcriptional profiles suggest that CD16 + and CD16 -Mo subsets originate from a common myeloid precursor, with CD16 + Mo being at a more advanced stage of myeloid differentiation and having distinct biological functions in vivo.
Previous studies in mice provide evidence for a developmental relationship between Ly6C high CCR2 high Gr1 + CX3 CR1 low and Ly6C low CCR2 low Gr1 -CX3CR1 high Mo (homologs of human CD16and CD16 + Mo, respectively), with Ly6C low CCR2 low Gr1 -CX3CR1 high Mo being more mature and derived from Ly6C high CCR2 high Gr1 + CX3CR1 low Mo [5, 41, 85] . Likewise, studies on human Mo demonstrated the ability of CD16 -CX3CR1 low Mo to differentiate into CD16 + CX3CR1 high Mo upon stimulation with TGF-β, IL-10, M-CSF, or CCL2 [17, [43] [44] [45] . Our comparative transcriptome analysis provides further evidence for the idea that CD16 -Mo originate from a common granulocyte-macrophage (GM) precursor and give rise to CD16 + Mo, which are more closely related to macrophages (MΦ) and dendritic cells (DC). CD16 -Mo preferentially expressed granulocyteassociated transcripts (i.e., CSF3R, formyl peptide receptor Differential expression of RARA mRNA and PSGL-1 epitopes CLA and M-DC8 on CD16 + and CD16monocytes M-DC8 1 (FPR1), the calgranulins S100A8, S100A9, and S100A12), and myeloid markers (i.e., CD14, MNDA, TREM-1, CD1d, and C1qR1/CD93), together with transcripts suggesting an increased potential for receptormediated endocytosis via molecules such as CD14 and FCGR1A/CD64 [85, 86] . In contrast, CD16 + Mo preferentially expressed MΦ (i.e., CSF1R/CD115, MafB, EGF module-containing mucin-like hormone receptor (EMR)1-3, CD97, and C3aR) [86] and DC markers (i.e., SIGLEC10, CD43, CXCL16, and RARA) [56, 74, 87, 88] . CD16 + Mo expressed higher levels of transcripts encoding the cysteine protease cathepsin L (CTSL), which contributes to phagocytic-endocytic proteolysis in DC for subsequent antigen presentation [64] . Upregulation of transcripts encoding dipeptidyl-peptidase I, CTSC [89] may further enhance antigen processing by CD16 + Mo or DC derived from these cells. Although some studies classified CD16 + Mo as DC based on their increased antigen presenting ability [14] [15] [16] and transcriptional profile similarities [16] , a recent compendium analysis of transcriptional profiles demonstrated that CD16 + HLA-DR + cells are more closely linked to myeloid CD14 + cells than to DC subsets in peripheral blood [90] . Our results demonstrate that CD16 + Mo share approximately 83% of their transcripts with CD16 -Mo, supporting the idea that these two Mo subsets are developmentally related.
Recruitment of CD16 + and CD16 -Mo into tissues is mediated via distinct molecular mechanisms [7, 8] . Our gene expression analysis confirms differential expression of adhesion molecules and chemokine receptors previously reported to be preferentially expressed on CD16 + Mo (i.e., LFA-1, PECAM/CD31, CX3CR1) and CD16 -Mo (i.e., CCR1, CCR2, and L-selectin/CD62L) [18] [19] [20] . We also identified new cell surface markers and other molecules that are differentially expressed in these Mo subsets and may influence their trafficking and migration into tissues. The tetraspanins MS4A4A and MS4A7, adhesion molecules SIGLEC10 and ICAM-2, and membrane-bound chemokine CXCL16 [56] were preferentially expressed by CD16 + Mo, whereas the tetraspanin MS4A6A, adhesion molecules CD99 and junctional adhesion molecule like (JAML or AMICA) [57] , and chemokine receptor FPR1 were preferentially expressed by CD16 -Mo. CD31 and CD99 are involved in distinct steps of Mo transendothelial migration [91, 92] . Expression of CXCL16, a chemokine expressed by DC [56] , on the surface of CD16 + Mo may facilitate interaction with CXCR6 + cells (i.e., NKT and activated CD4 + and CD8 + T-cells [56] ) and retention of CXCR6 + cells in tissues. Similar to mouse and rat CCR2 low CX3CR1 high Mo [37, 41] , CD16 + Mo expressed higher levels of SPN/CD43 (sialophorin, leukosialin, large sialoglycoprotein or gp115), a ligand for ICAM-1 [93, 94] , and the macrophage adhesion receptor sialoadhesin (Siglec-1) [95] . CD43 has both adhesive and anti-adhesive properties [96] , mediates DC maturation [88] , and contributes to regulation of immunological synapse formation [97] . CD47, a receptor for thrombospondin-1 (TSP-1), is preferentially expressed by CD16 + Mo. CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors by decreasing IL-12 and TNF-α production by Mo-derived DC [98, 99] . Consistent with these findings, CD16and CD16 + Mo may induce Th1 and Th2-like differentiation, respectively [100] . However, CD16 + Mo express IL-12RB1, which favors Th1 polarization [58] , whereas CD16 -Mo express receptors for the Th2 cytokines IL-6 and IL-13 [59] and the anti-Th1 cytokine, IL-27 [60, 61] . Accordingly, the influence of CD16 + and CD16 -Mo on Th1 versus Th2 polarization of immune responses is likely to be highly dependent on the local microenvironment within tissues.
CD16 + Mo expressed high levels of transcripts for RARA, which controls transcription of genes involved in cell trafficking and mucosal homing. RA imprints lymphocytes with non-skin mucosal homing properties by decreasing cutaneous lymphocyte-associated antigen (CLA, an epitope on PSGL-1) expression [83] and increasing expression of CCR9 and integrin beta 7, two mucosal addressins [77] . RA also controls reciprocal differentiation of Th17 and regulatory T cells [101] , modulates myeloid gene expression and differentiation [75] , and regulates survival and antigen presentation by DC [74] . Consistent with our hypothesis that the RARA pathway is activated in CD16 + Mo, we demonstrated CLA downregulation on these cells, together with upregulation of two RA-induced targets: SLP-76 [75] and CXCL16 [102] . RA induces mucosal-type DC, which produce TGF-β and thereby imprints T-cells for gut homing by inducing CCR9 and integrin beta 7 [76] . CD16 + Mo-derived MΦ and DC constitutively produce TGF-β [23, 100] , but whether they also instruct T-cells for gut homing remains to be determined.
KLF2 mRNA is expressed at very high levels and significantly upregulated in CD16 + compared to CD16 -Mo. KLF2 belongs to a family of zinc-finger transcription factors that is induced by PI3K signaling [103] and controls expression of several genes including those coding for CD62L, CCR7, integrin beta7, sphingosine-1-phosphate receptor (S1PR1) [73] , and lymphotoxin beta [104] . CCR7 and CD62L are essential for migration into lymph nodes, S1P1 regulates T-cell thymic egress and recirculation [105] , and integrin beta 7 mediates cell recruitment into Peyer's patches and mesenteric lymph nodes [106] . Together, these findings raise the possibility that preferential expression of KLF2 in CD16 + Mo may confer an increased potential for trafficking.
CD16 + compared to CD16 -Mo express very high levels of transcripts for cyclin-dependent kinase inhibitor 1C (CDKN1C or p57/KIP2) (18.4-fold increase) and metastasis suppressor 1 MTSS1 (5.7-fold increase). CDKN1C is a potent inhibitor of several G1 cyclin-dependent kinase (cdk) complexes, and negative regulator of G1/S cell cycle transition and cell proliferation [66] . CDKN1C [66] and MTSS1 [68] are candidate tumor suppressor genes, and their high expression is consistent with the inability of Mo to proliferate [7] . CDKN1C is induced by TGF-β [67] , a cytokine known to induce CD16 + Mo differentiation [17, 43] . Thus, our results are consistent with a potential link between TGF-β pathway activation and CD16 + Mo differentiation in vivo.
Several transcripts related to cell activation were upregulated in CD16 + Mo including LTB, TNFRSF8, leukocyte specific transcript 1 (LST1), IFITM1-3, HMOX1, superoxide dismutase-1 (SOD-1), tryptophanyl tRNA synthetase (WARS), and monoglyceride lipase (MGLL), indicating increased activation of CD16 + compared with CD16 -Mo. LST1 [107] , HMOX1 [108] , SOD-1, and WARS are induced by stimulation with lipopolysaccharide [109] . The role of LST1 in immune regulation remains elusive. HMOX1 modulates Mo inflammatory responsiveness by decreasing LPS-induced TNF and IL-1β expression [108] . WARS and indoleamine 2,3-dioxygenase (IDO) are responsible for tryptophan use in protein synthesis and degradation, respectively [63] . WARS was identified as a molecular marker for Mo differentiation into MΦ [110] and DC [111] . These results suggest increased activation of CD16 + compared to CD16 -Mo in vivo.
The CD16 + Mo subset includes two subsets with distinct levels of CD14 expression: CD14 high CD16 + and CD14 low CD16 + [11, 112] . CD14 high CD16 + Mo exhibit a phenotype intermediate between that of CD14 high CD16 neg and CD14 low CD16 + Mo in terms of adhesion molecule (e.g., CL62L) and chemokine receptor expression (e.g., CCR2, CXCR2, and CX3CR1) [18] . Both CD14 high CD16 + and CD14 low CD16 + Mo contributed to the transcriptional profile of CD16 + Mo in this study. The expression of some genes we identified as markers for CD16 + Mo may be distinct on CD14 high CD16 + and CD14 low CD16 + Mo. Consistent with this prediction, we demonstrated intermediate expression of CD115 and CD114 on CD14 high CD16 + Mo compared to CD14 high CD16 neg and CD14 low CD16 + Mo, and high expression of CD93 and C3aR1, similar to that on CD14 high CD16and CD14 low CD16 + Mo, respectively (Additional file 3). These findings suggest a developmental relationship between these Mo subsets in which CD14 high CD16 neg Mo, CD14 high CD16 + Mo, and CD14 low CD16 + Mo represent sequential stages of monocyte differentiation [41] .
Conclusion
Comparative transcriptome analysis of CD16 + and CD16 -Mo indicates that CD16 + Mo represent a more advanced stage of myeloid differentiation with a more MΦ -and DC-like transcription program, whereas CD16 -Mo are more closely related to a common myeloid precursor. Given the ability of CD16 + and CD16 -Mo to be recruited into specific tissues via distinct mechanisms, these Mo subsets are likely to give rise to DC and MΦ subpopulations with distinct phenotypes and roles in immunity and disease pathogenesis. Further studies to characterize phenotypic differences between CD16 + and CD16 -Moderived DC and MΦ are relevant for development of DCbased vaccines, and will also provide a better understanding of their functional roles in immune responses, inflammation, and disease pathogenesis.
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